Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase-2 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER; PREGNANCY AND GYNECOLOGY
THERAPEUTIC INDICATION: Osteoarthritis, Knee; Pancreatitis; Osteoarthritis; Pain; Pharyngitis; Rheumatic Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder, Major; Fatigue Syndrome, Chronic; Idiopathic Pulmonary Fibrosis; Kidney Diseases; Nasopharyngeal Neoplasms; Castleman Disease; Hearing Loss, Sensorineural; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Colitis, Ulcerative; Cytomegalovirus Infections; Cytomegalovirus Retinitis; Infections; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Prostanoid FP receptor agonist
ROUTE OF ADMINISTRATION: OPHTHALMIC
STATUS: Approved
THERAPEUTIC AREA: EYE; OTHER
THERAPEUTIC INDICATION: Exfoliation Syndrome; Glaucoma; Glaucoma, Open-Angle; Ocular Hypertension
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Human immunodeficiency virus type 1 reverse transcriptase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Hepatitis C; Hepatitis, Chronic; Insulin Resistance; Lymphoma; Tuberculosis; Communicable Diseases; Hepatitis D; Lipodystrophy; Liver Cirrhosis, Biliary; Acquired Immunodeficiency Syndrome; Severe Acute Respiratory Syndrome; HIV Infections; Hepatitis B, Chronic; Infections; Liver Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Prostanoid FP receptor agonist
ROUTE OF ADMINISTRATION: OPHTHALMIC; TOPICAL
STATUS: Approved
THERAPEUTIC AREA: EYE; OTHER
THERAPEUTIC INDICATION: Alopecia; Graves Ophthalmopathy; Glaucoma; Glaucoma, Open-Angle; Hypotrichosis; Ocular Hypertension
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Beta-2 adrenergic receptor agonist
ROUTE OF ADMINISTRATION: INHALATION
STATUS: Approved
THERAPEUTIC AREA: OTHER; RESPIRATORY
THERAPEUTIC INDICATION: Lung Neoplasms; Bronchiolitis Obliterans; Hypersensitivity; Respiratory Distress Syndrome; Severe Acute Respiratory Syndrome; Bronchiectasis; Bronchitis; Tobacco Use Disorder; Asthma; Bronchial Spasm; Bronchitis, Chronic; Emphysema; Pulmonary Disease, Chronic Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cardiovascular Diseases; Autistic Disorder; Borderline Personality Disorder; Depressive Disorder, Major; Mood Disorders; Phobia, Social; Anxiety; Bipolar Disorder; Dementia; Depressive Disorder; Schizophrenia; Psychotic Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: FK506-binding protein 1A inhibitor
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY
THERAPEUTIC INDICATION: Netherton Syndrome; Dermatitis, Seborrheic; Dry Eye Syndromes; Lichen Planus, Oral; Lichen Sclerosus et Atrophicus; Vitiligo; Dermatitis; Dermatitis, Perioral; Lichen Planus; Dermatitis, Atopic; Eczema
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Breast Neoplasms; Ischemic Stroke; Myocardial Infarction
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Estrogen receptor alpha agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Cystic Fibrosis; Diabetes Mellitus, Type 2; HIV Infections; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Infertility, Female; Leukemia, Lymphocytic, Chronic, B-Cell; Non-alcoholic Fatty Liver Disease; Bulimia; Bulimia Nervosa; Depressive Disorder; Endometrial Neoplasms; Hidradenitis Suppurativa; Hyperandrogenism; Metrorrhagia; Osteoporosis; Premenstrual Syndrome; Amenorrhea; Anorexia Nervosa; Bone Diseases, Metabolic; Breast Neoplasms; Dysmenorrhea; Migraine Disorders; Neural Tube Defects; Polycystic Ovary Syndrome; Pregnancy; Turner Syndrome; Acne Vulgaris; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acute Lung Injury; Carcinoma, Renal Cell; Colorectal Neoplasms; Desmoplastic Small Round Cell Tumor; Fibrosarcoma; Hematologic Neoplasms; Liver Cirrhosis; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms; Rhinitis, Allergic, Seasonal; Thymoma; Arthritis, Rheumatoid; Breast Neoplasms; Chordoma; Colonic Neoplasms; Fibroma; Fibromatosis, Aggressive; Glioblastoma; Hypereosinophilic Syndrome; Leukemia, Myeloid, Acute; Lung Neoplasms; Malaria, Falciparum; Melanoma; Scleroderma, Systemic; Spinal Cord Injuries; Stomach Neoplasms; Thyroid Neoplasms; Tuberculosis; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Hypertension, Pulmonary; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma; Severe Acute Respiratory Syndrome; Stroke; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Aspergillosis; Candidiasis, Invasive; Wounds and Injuries; Candidemia; Candidiasis; Candidiasis, Oral; Infections; Mycoses
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hepatitis; HIV Infections; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D; Liver Cirrhosis, Biliary; Severe Acute Respiratory Syndrome; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Bacterial penicillin-binding protein inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Urinary Tract Infections; Bronchitis, Chronic; Infections; Pharyngitis; Tonsillitis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Steroid 5-alpha-reductase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER; UROLOGY AND KIDNEY
THERAPEUTIC INDICATION: Aging; Amyotrophic Lateral Sclerosis; Bulbo-Spinal Atrophy, X-Linked; Prostatitis; Severe Acute Respiratory Syndrome; Alopecia; Hypogonadism; Prostatic Neoplasms, Castration-Resistant; Prostatic Hyperplasia; Prostatic Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mineralocorticoid receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Bulimia; Bulimia Nervosa; Depressive Disorder; Hidradenitis Suppurativa; Premenstrual Syndrome; Dysmenorrhea; Polycystic Ovary Syndrome; Acne Vulgaris
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Pain; Migraine Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypotension, Orthostatic; Lecithin Cholesterol Acyltransferase Deficiency; Memory Disorders; Obesity; Subarachnoid Hemorrhage; Cocaine-Related Disorders; HIV Infections; Psychotic Disorders; Tobacco Use Disorder; Alzheimer Disease; Anxiety; Autistic Disorder; Dementia, Vascular; Depressive Disorder; Lewy Body Disease; Schizophrenia; Dementia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amphetamine-Related Disorders; Cocaine-Related Disorders; Orthostatic Intolerance; Tobacco Use Disorder; Alcoholism; Cognitive Dysfunction; Hypotension, Orthostatic; Marijuana Abuse; Opioid-Related Disorders; Phobia, Social; Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Substance-Related Disorders; Tourette Syndrome; Autistic Disorder; Neoplasms; Schizophrenia; Attention Deficit Disorder with Hyperactivity
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Dyspepsia; Gastroesophageal Reflux; Constipation
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alzheimer Disease; Hepatitis C; Aphasia; Borderline Personality Disorder; Carcinoma, Pancreatic Ductal; Cocaine-Related Disorders; Digestive System Diseases; Fibromyalgia; Panic Disorder; Phobia, Social; Phobic Disorders; Renal Insufficiency, Chronic; Stress Disorders, Post-Traumatic; Stroke; Substance-Related Disorders; Anxiety; Anxiety Disorders; Arthritis, Rheumatoid; Bipolar Disorder; Carcinoma; Dementia; Depressive Disorder, Major; Hypertension, Pulmonary; Neoplasms; Obsessive-Compulsive Disorder; Schizophrenia; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor partial agonist
ROUTE OF ADMINISTRATION: INTRAMUSCULAR; ORAL; ORALLY DISINTEGRATING
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Amphetamine-Related Disorders; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Cocaine-Related Disorders; Fragile X Syndrome; Obsessive-Compulsive Disorder; Alcoholism; Alzheimer Disease; Anorexia Nervosa; Anxiety; Child Development Disorders, Pervasive; Dementia; Depression, Postpartum; Stress Disorders, Post-Traumatic; Tourette Syndrome; Aggression; Autistic Disorder; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Major; Psychomotor Agitation; Psychotic Disorders; Schizophrenia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cytochrome P450 51 inhibitor
ROUTE OF ADMINISTRATION: INJECTION; INTRAVENOUS; IV (INFUSION); ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Asthma; Graft vs Host Disease; HIV Infections; Hematologic Neoplasms; Keratitis; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms; Neutropenia; Aspergillosis, Allergic Bronchopulmonary; Myelodysplastic Syndromes; Candidiasis, Invasive; Leukemia; Leukemia, Myeloid, Acute; Mycoses; Neuroaspergillosis; Aspergillosis; Candidemia; Candidiasis; Fusariosis; Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA polymerase/reverse transcriptase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Cytomegalovirus Infections; HIV Infections; Hepatitis B, Chronic; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Prostanoid IP receptor agonist
ROUTE OF ADMINISTRATION: INHALATION; INTRAVENOUS; IV (INFUSION); SUBCUTANEOUS
STATUS: Approved
THERAPEUTIC AREA: CARDIOVASCULAR; OTHER; RESPIRATORY
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 1; Diabetic Foot; Reperfusion Injury; Scleroderma, Systemic; Hernias, Diaphragmatic, Congenital; Ischemia; Peripheral Vascular Diseases; Persistent Fetal Circulation Syndrome; Pulmonary Disease, Chronic Obstructive; Respiratory Distress Syndrome; Familial Primary Pulmonary Hypertension; Idiopathic Pulmonary Fibrosis; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Thrombosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Common Cold; Infections; Respiratory Tract Infections; Cough; Fever; Headache; Sinusitis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Serotonin 4 (5-HT4) receptor partial agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: GASTROINTESTINAL; OTHER
THERAPEUTIC INDICATION: Constipation; Irritable Bowel Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Estrogen receptor antagonist
ROUTE OF ADMINISTRATION: INTRAMUSCULAR
STATUS: Approved
THERAPEUTIC AREA: CANCER
THERAPEUTIC INDICATION: Carcinoma, Ductal; Carcinoma, Squamous Cell; Colorectal Neoplasms; Hereditary Breast and Ovarian Cancer Syndrome; Lymphoma; Lymphoma, Non-Hodgkin; Mesothelioma; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Urinary Bladder Neoplasms; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fibrous Dysplasia, Polyostotic; Genital Neoplasms, Female; Hypertension, Pulmonary; Lung Neoplasms; Lupus Erythematosus, Systemic; Ovarian Neoplasms; Prostatic Neoplasms; Puberty, Precocious; Sarcoma, Endometrial Stromal; Uterine Neoplasms; Carcinoma, Lobular; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Niemann-Pick C1-like protein 1 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: HIV Infections; Hepatitis C, Chronic; Hepatitis D; Non-alcoholic Fatty Liver Disease; Aortic Valve Stenosis; Atherosclerosis; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypertension; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Syndrome; Metabolism, Inborn Errors; Myocardial Infarction; Cardiovascular Diseases; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA inhibitor
ROUTE OF ADMINISTRATION: INJECTION; INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: CANCER; OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mineralocorticoid receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CARDIOVASCULAR; OTHER
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 2; Atrial Fibrillation; Breast Neoplasms; Central Serous Chorioretinopathy; Diabetic Nephropathies; Hyperparathyroidism, Primary; Cardiomyopathies; Essential Hypertension; Muscular Dystrophy, Duchenne; Renal Insufficiency, Chronic; Cardiovascular Diseases; Heart Failure; Hypertension; Myocardial Infarction; Stroke
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: 4-hydroxyphenylpyruvate dioxygenase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER; PEDIATRICS
THERAPEUTIC INDICATION: Albinism; Alkaptonuria; Tyrosinemias
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Pyruvate:ferredoxin oxidoreductase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER; PEDIATRICS
THERAPEUTIC INDICATION: HIV Infections; Irritable Bowel Syndrome; Kidney Diseases; Liver Diseases; Bronchiolitis; Crohn Disease; Gastroenteritis; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Malnutrition; Periodontitis; Tuberculosis; Amebiasis; Arthritis, Rheumatoid; Brain Diseases; Clostridium Infections; Cryptosporidiosis; Dyspepsia; Enterocolitis, Pseudomembranous; Helicobacter Infections; Influenza, Human; Peritonitis; Respiratory Tract Diseases; Severe Acute Respiratory Syndrome; Diarrhea
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hyperpigmentation; Lentigo; Melanosis